Acute radiation dermatitis (ARD) is a common complication in cancer patients undergoing radiation therapy.
A systematic review of the latest research on the prevention and management of acute radiation dermatitis (ARD) entitled "MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review" was recently published".
The study was conducted by the Oncodermatology study group of MASCC (Multinational Association Of Supportive Care In Cancer), an international, non-profit and multidisciplinary organisation dedicated to research and education of supportive care for oncological patients.
The authors conducted a comprehensive search of multiple databases and included randomised and nonrandomised studies that met the inclusion criteria. 5173 articles published between 1946 and January 2023 were reviewed, of which 235 were selected for analysis.
Photobiomodulation therapy (PBMT) emerged as one of the most promising treatments. The authors found that PBMT was more efficient in the prevention of ARD compared to standard care and/or placebo, particularly in patients with breast cancer.
Of the 5 randomised studies on PBMT that were selected and analysed in the review, 2 were conducted by Dr Robijin's group using the M6 robotic laser device, from the MLS® family.
Prevention of Acute Radiodermatitis by Photobiomodulation: A Randomized, Placebo-Controlled Trial in Breast Cancer Patients (TRANSDERMIS Trial)
J. Robijns, S. Censabella, S. Claes, L. Pannekoeke, L. Bussé, D. Colson, I. Kaminski, P. Bulens, A. Maes, L. Noé, M. Brosens, A. Timmermans, I. Lambrichts, V. Somers, J. Mebis
Lasers in Surgery and Medicine, 9999:1-9 (2018)
Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients
J. Robijns, S. Censabella, S. Claes, L. Pannekoeke, L. Bussé, D. Colson, I. Kaminski, J. Lodewijckx, P. Bulens, A. Maes, L. Noé, M. Brosens, A. Timmermans, I. Lambrichts, V. Somers, J. Mebis
Support Care Cancer, 2018
The quality of studies on the application of MLS® Laser Therapy in the prevention of ARD in breast cancer patients was considered good and potentially opens the door to future applications.
It is important to underline that in general the scientific evidence in this area is still limited and that the use of laser therapy in cancer patients is still under observation and the subject of multiple studies.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.